Just as we can decompose the US #COVID19 epidemic into a B.1.1.7 epidemic and a non-B.1.1.7 epidemic, we can further partition by variants of concern B.1.1.7, B.1.351 and P.1, where it's clear that P.1 has been gaining ground. 1/13
Here, using data from @GISAID, we see that in terms of frequencies across the US, P.1 has been undergoing more rapid logistic growth in frequency than B.1.1.7, while B.1.351 has been slower than B.1.1.7. 2/13
I'm plotting this with the unusual "logit" y-axis (with 1%, 10%, 50%, etc...) because a straight line in logit space is indicative of logistic growth. This sort of plot makes it easy to compare logistic growth rate of frequency between lineages with different frequencies. 3/13
We generally see more rapid logistic growth of P.1 across individual states as well. These 9 were chosen as those with the most data. All these plots only go to Apr 14, as there is a necessary lag to the genomic data as samples are processed. 4/13
The observation of faster logistic growth of P.1 compared to B.1.1.7 suggests that P.1 may have a transmission advantage over B.1.1.7 in the US and may continue to gain ground even as B.1.1.7 comes to dominate the virus population. 5/13
Given that P.1 frequency is growing rapidly, but overall cases are generally falling, the question becomes are vaccines and other control measures enough to curb spread of P.1 in absolute case counts? 6/13
To address this we can take these frequency estimates alongside case counts from @CDCGov and use frequencies to partition case counts by variant. Doing so results in this plot for the US, where the large majority of the epidemic is due to B.1.1.7 and non-B.1.351/P.1 viruses. 7/13
However, plotting partitioned case counts on a log-scale clearly shows the continued growth in absolute case counts of P.1. 8/13
We can use the same approach with state-level case counts and frequency data to estimate case counts for B.1.1.7, B.1.351 and P.1 variants. Here, we see that P.1 is still a minor (but growing) contribution but where some states like IL and WA have a larger P.1 share. 9/13
Looking at this same data on a log-scale makes the absolute growth of P.1 cases in CA, FL, IL, MA, MI, NY and WA quite clear. 10/13
Vaccination will continue bring down overall transmission rate, where I expect transmission chains of non-variant viruses to largely die out in the coming weeks. Variant viruses B.1.1.7 and P.1 raise the bar for the level of vaccination required to control the epidemic. 11/13
Mutations in P.1 suggest partial escape from antibody binding, which is borne out in drops in neutralization titer. I would expect P.1 to show some decrease in vaccine effectiveness, but remain largely effective. Figure from Wu et al (nejm.org/doi/full/10.10…). 12/13
Growth of P.1 alongside probable decrease in vaccine effectiveness suggests it's all the more important to get as many people vaccinated as possible as vaccination can still suppress circulation of P.1; it's just that the bar for herd immunity is higher. 13/13
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Currently, the US is reporting about 54k daily cases of COVID-19 (16 per 100k per capita) and the UK is reporting about 4k (6 per 100k). This seems comfortingly low compared to even this summer's BA.5 wave and let alone last winter's BA.1 wave. Figure from @OurWorldInData. 1/16
However, at this point, nearly all infections will be in individuals with prior immunity from vaccination or infection and this combined with a roll back in testing makes it unclear how to interpret current case counts compared to previous time periods. 2/16
We're interested in the case detection rate or the ratio of underlying new infections compared to reported cases. Throughout much of 2020 and 2021, I had a working estimate of 1 infection in ~3.5 getting reported as a case. 3/16
Largely through partial immune escape, lineage BA.5 viruses resulted in sizable epidemics throughout much of the world. However, in most countries these epidemics are now beginning to wind down. What do we expect after BA.5? 1/10
Lineage BA.2.75 (aka 'Centaurus') has been high on watch lists due to sustained increase in frequency in India combined with the presence of multiple mutations to spike protein. We now have enough sampled BA.2.75 viruses from outside India to make some initial conclusions. 2/10
If we look at frequency data we see sustained logistic growth of BA.2.75 in India, Japan, Singapore and the US. Critically, in India it is clearly displacing BA.5. 3/10
Based on the experience in winter 2020/2021, seasonal influence on SARS-CoV-2 transmission is quite clear, but much of the Northern Hemisphere is currently experiencing large summer epidemics driven the spread of evolved BA.5 viruses. 1/11
It's necessarily fraught to try to make predictions of seasonal circulation patterns going forwards, but we can gain some intuition from simple epidemiological models. 2/11
In particular, we can use an SIRS system in which individuals go from Susceptible to Infected to Recovered, and then return to the Susceptible class due to immune waning / antigenic drift of the virus. 3/11
There seems to be a worry that telling people we've exited the "pandemic phase" will lead to further reduced precautions. As always however, I think it's best not to conduct messaging for intended behavioral effect and just try to make scientifically accurate statements. 1/5
Given vaccination and infection, the US and global population now has widespread immunity to SARS-CoV-2 and deaths per-infection are about 10 times lower than they were pre-immunity in 2020 with a ballpark IFR of 0.05% (though this will vary by immunity and age demographics). 2/5
You can see this reduction in mortality rate in looking at projections of deaths from lagged-cases keyed to early case fatality rate. 3/5
The @US_FDA VRBPAC committee will be meeting tomorrow to discuss variant-specific COVID-19 vaccines (fda.gov/advisory-commi…). Based on present observations, I would argue that the most important metric to optimize are titers against BA.4/BA.5 viruses. 1/10
We've seen repeated replacement of SARS-CoV-2 variants during 2022, first of Delta by Omicron BA.1 and then by sub-lineages of Omicron, with BA.2 replacing BA.1 and now with BA.4/BA.5 replacing BA.2. 2/10
Viruses have been evolving to be higher fitness through both increases in intrinsic transmissibility (seen in BA.2 vs BA.1) as well as escape from existing population immunity (seen in Omicron vs Delta as well as BA.4/BA.5 vs BA.2). 3/10
Global monkeypox confirmed and suspected cases compiled by @globaldothealth show initial rapid increase as case-based surveillance comes online, followed by slower continued growth. 1/10
This is data from github.com/globaldothealt… and has had a 7-day smoothing applied and all y-axes are shown on a log scale. 2/10
If we focus on the last 11 days, we can see steady exponential growth in global cases with a ~7.7 day doubling. 3/10